Smith & Nephew (LON:SN) Stock Rating Reaffirmed by Barclays

Barclays reissued their equal weight rating on shares of Smith & Nephew (LON:SNFree Report) in a report issued on Friday morning, MarketBeat Ratings reports. They currently have a GBX 1,150 ($14.52) target price on the stock.

SN has been the topic of a number of other research reports. JPMorgan Chase & Co. reissued an overweight rating and issued a GBX 1,248 ($15.76) target price on shares of Smith & Nephew in a research report on Thursday, November 30th. Berenberg Bank reaffirmed a buy rating and set a GBX 1,500 ($18.94) price objective on shares of Smith & Nephew in a research report on Thursday, November 30th. Finally, Royal Bank of Canada cut their price objective on Smith & Nephew from GBX 1,600 ($20.21) to GBX 1,500 ($18.94) and set an outperform rating on the stock in a research report on Monday, November 6th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of GBX 1,361.60 ($17.20).

Get Our Latest Analysis on Smith & Nephew

Smith & Nephew Stock Up 0.5 %

SN stock opened at GBX 1,098 ($13.87) on Friday. The firm has a market cap of £9.60 billion, a PE ratio of 5,462.50, a PEG ratio of 0.49 and a beta of 0.50. The company has a debt-to-equity ratio of 58.09, a quick ratio of 0.84 and a current ratio of 2.19. The firm’s 50 day moving average price is GBX 1,074.87 and its 200-day moving average price is GBX 1,045.13. Smith & Nephew has a one year low of GBX 887 ($11.20) and a one year high of GBX 1,316.75 ($16.63).

About Smith & Nephew

(Get Free Report)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

See Also

Analyst Recommendations for Smith & Nephew (LON:SN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with's FREE daily email newsletter.